



Monsenso A/S issues warrants to management and employees

31.3.2026 12:37:30 CEST | Monsenso | Other information disclosed according to the rules of the Exchange

Company announcement no. 04-2026

Copenhagen, 2026.03.31

The Board of Directors has decided to grant warrants in the Company with the purpose of:

- Ensuring that shareholders and the Company's Executive Management have the same interests and that everyone makes a special effort for value creation.
- Retaining the Executive Management and employees of the Company.

Warrants will be granted in accordance with § 5.3 of the company's articles of association.

Warrants granted to the Company's employees and Executive Management amount to 5,000,000 warrants which offer the right to subscribe for a nominal DKK 500,000 shares in the Company corresponding to 7,49 % of the Company's total outstanding share capital.

The exercise price is 0.11 DKK per warrant, which corresponds to the market price calculated as a 30-day weighted average. The value of each warrant can be calculated at DKK 0.035 based on an interest rate of 7% p.a. and volatility of the company's shares of 5.7% (using the Black-Scholes formula).

These warrants are granted as a one-time grant, and vesting is subject to the terms and conditions set by the Board of Directors where warrants vest with 1/36 per month from 1 May 2026 to and including 30 April 2029. Vesting is subject to the recipient's employment in the Company at the time of vesting.

Warrants will be granted free of charge and can be exercised twice a year after publication of the Company's annual and semiannual reports within an exercise window of 2 weeks. Warrants that are not exercised on 31 August 2033 will lapse.

Monsenso's share capital amounts to a nominal value of DKK 6,677,350.20 divided into 66,773,502 shares of DKK 0.10 each.

Any inquiries regarding this notice should be directed to

Monsenso

CEO
Thomas Lethenborg
Tel +45 21 29 88 27
E-mail: lethenborg@monsensos.com

Chairman of the board
Peter Mørch Eriksen
E-mail: Petermorcheriksen@outlook.com

Certified Adviser:

HC Andersen Capital
Bredgade 23, 2
1264 København K

About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com

Attachments

- [Download announcement as PDF.pdf](#)